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Abstract
Pulmonary hypertension (PH) is diagnosed in 40–50% of the patients with end-stage diffuse parenchymal lung diseases (DPLD), 
and it is associated with significant worsening of life expectancy. Latest ERS/ESC guidelines recommend best available treatment 
of DPLD, and long-term oxygen therapy in the patients with PaO2 less than 60 mm Hg. Pulmonary arterial hypertension (PAH)-tar-
geted drugs are not recommended in PH-DPLD patients, due to the risk of increasing the ventilation-perfusion mismatch, and 
consequently worsening of hypoxaemia. Nevertheless, PAH-oriented treatment may be beneficial to selected groups of patients. 
The authors try to find the answer to several important questions: is there any benefit of PAH-specific therapy in PH-DPLD, who 
should be the candidate for PAH-specific therapy, what class of drugs is most promising, and what outcome measures should 
be employed?
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Introduction
Pulmonary hypertension (PH) due to lung 
diseases is a precapillary PH, defined as mean 
pulmonary artery pressure (mPAP) equal or higher 
than 25 mm Hg and pulmonary artery wedge pres-
sure (PAWP) not exceeding 15 mm Hg assessed 
during right heart catheterisation (RHC) [1, 2]. In 
the latest ERS/ESC guidelines, severe PH due to 
lung diseases was characterised as mPAP > 35 
mm Hg or mPAP ≥ 25 mm Hg with cardiac index 
< 2.5 l/min/m2 [1]. 
According to recent ERS/ESC classification 
(Table 1), diffuse parenchymal lung diseases 
(DPLD) as the cause of PH are included in two 
groups: group 3 — where PH is regarded as the 
result of hypoxia and/or interstitial lung patholo-
gy, and group 5 — where multiple possible causes 
of PH may be taken into account [1]. 
Most cases of PH-DPLD concern patients 
with advanced lung disease with extensive 
lung fibrosis, nevertheless, in sarcoidosis PH 
may be related to other mechanisms, mostly to 
vasculopathy, found both in stage I–III patients 
and in those in stage IV [3, 4]. The presence of 
PH in DPLD is an adverse prognostic factor. Life 
expectancy is even worse in those presenting 
with severe PH. 
Current ERS/ESC treatment guidelines rec-
ommend best available treatment of DPLD and 
long-term oxygen therapy in patients with hy-
poxaemia [1]. Pulmonary arterial hypertension 
(PAH)-specific drugs are not advised in this 
population, as there is no objective proof of their 
efficacy. Nevertheless, there are many publica-
tions concerning the therapeutic benefit of such 
treatment given as off-label therapy in individual 
patients. 
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Table 1.  Classification of pulmonary hypertension accor-
ding to recent ERS/ESC guidelines [1]
1. Pulmonary arterial hypertension
 1.1 Idiopathic PAH
 1.2 Heritable PAH
  1.2.1 BMPR2
  1.2.2 ALK-1, ENG, SMAD 9, CAV1, KCNK3
  1.2.3 Unknown
 1.3 Drug and toxin induced
 1.4 Associated with:
  1.4.1 Connective tissue disease
  1.4.2 HIV infection
  1.4.3 Portal hypertension
  1.4.4 Congenital heart disease
  1.4.5 Schistosomiasis
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary 
haemangiomatosis
1” Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension due to left heart disease
 2.1 Left ventricular systolic dysfunction
 2.2 Left ventricular diastolic dysfunction
 2.3 Valvular disease
 2.4 Congenital/acquired left heart inflow/outflow tract  
obstruction and congenital cardiomyopathies
3. Pulmonary hypertension due to lung diseases and/or hypoxia
 3.1 Chronic obstructive pulmonary disease
 3.2 Interstitial lung disease
 3.3 Other pulmonary diseases with mixed restrictive  
and obstructive pattern
 3.4 Sleep-disordered breathing
 3.5 Alveolar hypoventilation disorders
 3.6 Chronic exposure to high altitude
 3.7 Developmental lung diseases
4. Chronic thromboembolic pulmonary hypertension and other 
pulmonary artery obstructions
 4.1 Chronic thromboembolic pulmonary hypertension
 4.2 Other pulmonary artery obstructions
  4.2.1 Angiosarcoma
  4.2.2 Other intravascular tumors
  4.2.3 Arteritis
  4.2.4 Congenital pulmonary arteries stenoses
  4.2.5 Parasites (hydatidosis)
5. Pulmonary hypertension with unclear multifactorial mecha-
nisms
 5.1 Hematologic disorders: chronic hemolytic anemia,  
myeloproliferative disorders, splenectomy
 5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomyomatosis
 5.3 Metabolic disorders: glycogen storage disease, Gaucher 
disease, thyroid disorders, 
 5.4 Others: pulmonary tumoral thrombotic microangiopathy, 
fibrosing mediastinitis, chronic renal failure, segmental PH
BMPR — bone morphogenic protein receptor type II; CAV1 — caveolin-1; 
ENG — endoglin; HIV— human immunodeficiency virus; PAH — pulmonary 
arterial hypertension  
In the present review, we tried to summarise 
the up-to date information on best available tre-
atment options possibly influencing PH-DPLD 
and to analyse the results of recently published 
clinical trials with PAH-specific drugs. DPLD be-
longing to group 3 such as idiopathic pulmonary 
fibrosis (IPF), other types of idiopathic interstitial 
pneumonia and hypersensitivity pneumonitis 
(HP), as well as those belonging to group 5 such 
as sarcoidosis, were included. 
Epidemiology of PH-DPLD
The data on the frequency of PH in DPLD relate 
mostly to patients with advanced lung diseases in 
whom RHC was performed before lung transplan-
tation. Three large studies performed in end-stage 
IPF found PH in 43–49% of cases [5–7]. Baughman 
et al. [8] diagnosed precapillary PH in 39% of sar-
coidosis patients presenting with dyspnoea despite 
immunosuppressive treatment, and Oliveira et 
al. [9] confirmed PH in 44% of the patients with 
chronic hypersensitivity pneumonitis (cHP). The 
prevalence of severe PH was estimated at 2–9% in 
end-stage IPF [5, 10], 10% in cHP patients [7], and 
18% in sarcoidosis refractory to immunosuppres-
sive therapy [8]. The recent multicentre Japanese 
study of Tanabe et al. [11] confirmed the presence of 
severe PH in 4% of patients with IPF, 8% of patients 
with combined pulmonary fibrosis and emphysema 
(CPFE), and 10% of patients with interstitial lung 
diseases due to collagen tissue disease (CTD).
Pathogenesis of PH-DPLD and differential 
diagnosis of PH causes in DPLD patients
The presence of inflammatory or fibrotic 
lung disease results in alveolar hypoxia. Alveolar 
hypoxia generates the hypoxic vasoconstriction 
in the small precapillary arteries, which is an 
adaptive mechanism diminishing blood flow 
through the hypoventilated parts of the lung [12]. 
Chronic hypoxia causes remodelling of pul-
monary arteries (PA): endothelial dysfunction, 
intimal fibrosis, and medial hypertrophy [12, 13]. 
Awano et al. [14] have recently reported on the 
morphology of PA remodelling in the autopsy spe-
cimens obtained from the patients with CPFE, IPF 
and emphysema alone. The most extensive vascu-
lar changes were described in the fibrotic areas, 
less extensive in the emphysematous parts of the 
lung. Interestingly, some arterial pathology was 
also found in the areas of preserved lung paren-
chyma, especially in the patients with CPFE [14]. 
PA remodelling escalates the imbalance be-
tween vascular vasodilator and vasoconstrictor 
factors, i.e. decrease in endogenic nitric oxide 
(NO) and increase in endothelin-1 [15].
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The lung opacities seen in DPLD may result 
in the compression or distortion of pulmonary 
vessels. The phenomenon can be observed not 
only in the fibrotic areas but also in the hype-
rinflated parts of the lungs [12]. It may lead to 
turbulent blood flow and cause the increased 
shear stress that augments vasculopathy.
Pulmonary arteries may also be directly 
involved in the course of DPLD, especially in 
sarcoidosis [3, 16, 17], pulmonary Langerhans 
cell histiocytosis [18, 19], and lymphangioleio-
miomatosis [12]. 
The differential diagnosis of other PH-rela-
ted processes in DPLD patients should include 
postcapillary PH due to left heart insufficiency. 
The probability of postcapillary PH is highest in 
IPF patients because of frequent coexistence of 
circulatory disorders resulting from advanced 
age and smoking history [20]. In sarcoidosis and 
scleroderma, postcapillary PH may develop due 
to direct cardiac involvement as well [8, 21]. 
Finally, venous thromboembolic disease 
(VTE) should be taken into consideration as 
a factor contributing to severe PH development 
in patients with DPLD. According to recent publi-
cations, VTE incidence is increased both in IPF 
and in sarcoidosis, compared to reference healthy 
population [22–24]. Thus, CT-angiography sho-
uld always be considered as a part of differential 
work-up in individuals with severe PH-DPLD. 
Prognosis of PH-DPLD patients
The development of PH in DPLD patients 
is one of adverse prognostic factors. Baughman 
et al. [8] observed the worst survival in cases of 
PH due to lung disease, and much better progno-
sis in subjects with PH due to left heart failure, in 
the group of sarcoidosis patients. Takahashi et al. 
[25] found mPAP to be a significant independent 
survival predictor in DPLD associated with CTD. 
Data obtained from PH registries indicate that 
prognosis of the patients with severe PH-DPLD 
is extremely poor, with only 20-30% of patients 
surviving 3 years [26, 27].
Current treatment options in PH-DPLD
Recent ERS/ESC guidelines postulate the 
best available treatment of DPLD, and long-term 
oxygen therapy (LTOT) for the patients in whom 
resting partial oxygen pressure is lower than 
60 mm Hg [1]. Although LTOT may improve the 
quality of life in PH-DPLD, its influence on survi-
val has not been proved [1]. 
Current treatment options for chronic fibrotic 
lung diseases have been summarised recently by 
Adegunsoye et al. [28]. The immunosuppressive 
therapy is often used in cHP, sarcoidosis and CTD
-associated interstitial lung diseases to diminish 
an inflammatory component of lung infiltrates. 
The positive influence of such treatment on PH 
due to DPLD was reported by Sanchez et al. [29] 
in patients with systemic lupus erythematosus 
and mixed connective tissue disease, but not in 
systemic sclerosis (SSc). 
The recent development and approval of 
anti-fibrotic drugs, pirfenidone and nintedanib, 
in IPF, was based on clinical trials showing the 
reduced rate of lung function decline [30–32]. The 
influence of pirfenidone or nintedanib on PH due 
to IPF is not easy to establish, because most trials 
excluded patients with end-stage lung disease, 
and because PH was not reported as a treatment 
related parameter [28, 33]. The mode of action of 
these drugs, affecting properties of fibroblasts and 
myofibroblasts, suggest their possible usefulness 
in IPF-related vasculopathy [34]. 
Rationale for PAH-specific drugs use in PH-DPLD
The experts’ opinion concerning contradic-
tions to the use of PAH-specific drugs in DPLD 
was based on the negative outcome of RCTs with 
endothelin receptor antagonists (ERA) — bosen-
tan, macitentan and ambrisentan [35–38] and 
5-phosphodiesterase inhibitor (5PDEi) — silde-
nafil [39]. Ambrisentan has been even found to 
increase mortality [38], and recent international 
guidelines stated against ambrisentan use in IPF 
patients [40]. Nevertheless, the results of the ci-
ted RCTs should not be extrapolated to PH-DPLD 
patients because the knowledge about PH status 
of the patients included in the trials was lacking. 
On the other hand, there were many case 
reports and open label studies published, sup-
porting thesis that PAH-specific treatment may be 
beneficial to selected PH-DPLD patients [41–43]. 
Saggar et al. [43] reported on 15 patients with 
end-stage lung fibrosis and severe PH, who expe-
rienced a substantial haemodynamic improve-
ment being treated with intravenous treprostinil 
in an open prospective study. 
Han et al. [44] reported significant increase in 
6-minute walking distance (6MWD) in the course 
of sildenafil therapy compared to placebo in IPF 
patients presenting with right ventricular systolic 
dysfunction (STEP-IPF sub-study). 
Zimmerman et al. [45] found significant 
haemodynamic improvement in 10 ILD patients 
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treated with 5PDEi in the open label observatio-
nal study.
The only positive randomised clinical trial 
(RCT) concerning PH-DPLD was published by 
Baughman et al. [46]. A significant decrease in 
mPAP was found in 23 PH-sarcoidosis patients 
who received 16-weeks bosentan treatment, 
compared to the placebo arm [46]. Other RCTs 
concerning PAH-specific treatment in patients 
with PH-DPLD were negative [47, 48]. Rise IIP, 
phase-2 study with riociguat in PH-DPLD, has 
been closed prematurely due to increased death 
rate in an active treatment arm [48]. 
The contradictory results of the studies cause 
a great need for better identification of those PH
-DPLD patients who may benefit from vasoactive 
therapy. Concerns regarding the best choice of 
candidates for such treatment, possible differen-
ces in efficacy of various classes of PAH-specific 
drugs, and optimal outcome measures, will be 
discussed in the following part of the text.
Does the result of PAH-specific therapy in PH-DPLD 
patients depend on the severity of PH?
The rationale for the use of the PAH-specific 
drugs in PH-DPLD is based on the concept that 
they might slow down the development of vascu-
lar remodelling, due to their antiproliferative 
effect. This result may be observed after, at least, 
several months of treatment. Therefore, it would 
be important to consider PAH-specific therapy 
mainly in patients with longer life expectancy. 
At present, however, according to recent 
opinion of experts published as a result of the 5th 
World Symposium on Pulmonary Hypertension 
in Nice (Table 2), only patients with severe PH 
(mPAP >35 mm Hg) in the course of DPLD sho-
uld be considered as candidates for trials with 
PAH-specific drugs [2]. 
Brewis et al. [26] published recently the re-
sults of PAH-specific therapy in 118 patients with 
severe PH due to lung diseases, who were inc-
luded in the Scottish PH-registry. The group inc-
luded 22 patients with interstitial lung diseases, 
and the majority of them was treated with 5PDEi. 
These patients presented with well-preserved 
lung volumes, but very low diffusing capacity for 
carbon monoxide (DLCO) and severe functional 
and haemodynamic compromise, as well as extre-
mely high N-terminal brain natriuretic propeptide 
(NT-proBNP) serum levels (Table 3). PAH-specific 
therapy resulted in the significant decrease in 
NT-proBNP, but no significant improvement in 
6MWD and NYHA class were observed [26]. The 
prognosis was poor, 3-year survival rate was 20% 
[26]. Change in NT-proBNP serum levels in the 
course of PAH-specific therapy independently 
predicted survival [26].
Hoeper et al. [27] published the results of 
PAH-specific therapy (mostly 5PDEi) in 113 IPF 
and 38 non-specific interstitial pneumonia (NSIP) 
patients included in the COMPERA registry. They 
presented with less haemodynamic compromise 
than the group described by Brewis et al. [26] 
(Table 3). As expected, their initial exercise capaci-
ty was better, and NT-pro BNP serum concentration 
was lower than in the Scottish group [27]. Lung vo-
lumes and DLCO were comparable to the previous 
study. The authors defined response to treatment 
as an increase in 6MWD by at least 20 meters and/ 
/or the functional class (FC) improvement after 
13 weeks of therapy [27]. The percentage of tre-
atment responders was comparable in the groups 
of patients with severe and non-severe PH. The 
responders had significantly better life expectancy 
compared to non-responders: 3-year survival rates 
were 41.7% and 33.9% respectively, p = 0.048 [27]. 
The results of the above mentioned studies 
indicate that in the patients with severe PH-ILD, 
Table 2.  Recommendations concerning management of PH in the patients with lung diseases, according to experts on 5th 
World PH Conference in Nice [2]
Clinical characteristics mPAP < 25 mm Hg mPAP 25–34 mm Hg mPAP ≥ 35 mm Hg
FEV1 ≥ 60% pred. (COPD)
FVC ≥ 70% pred. (IPF)
CT: absence of or modest 
abnormalities
No PH, 
No PAH specific treat-
ment recommended
PH classification uncertain
No data supporting treat-
ment with PAH specific 
drugs
PH classification uncertain: discrimination  
between PAH with concomitant lung disease 
(group 1) or PH caused by lung disease (group 3)
Refer to a center with expertise in both PH and 
chronic lung disease
FEV1 < 60%pred. (COPD)
FVC < 70% pred.  (IPF)
CT: Combined pulmonary 
fibrosis and emphysema 
No PH
No PAH specific treat-
ment recommended
PH-COPD, PH-IPF, PH- CPFE
No data currently support 
treatment with PAH-specific  
drugs
Severe PH-COPD, severe PH-IPF, severe PH-CPFE
Refer to a center with expertise in both PH and 
chronic lung disease for individualized patient 
care because of poor prognosis: randomized  
controlled trials required
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Table 3.  Comparison of patients’ demographics and baseline characteristics in  two PH-registries reporting the efficacy  
of PAH-specific therapy in PH-DPLD
Reference RHC
Mean (SD)
No of pts/ 
/diagnosis
TLC
 %pred.
Mean (SD)
DLCO %pred.
Mean  (SD)
6MWD m
Mean  (SD)
NT-proBNP pg/ml
Median (range)
Brewis et al. ERJ 
2015 [26]
mPAP 46 (8) mm Hg, 
mRAP 10 (6) mm Hg
CI 1.9 (0.5) l/min/m2
22 ILD 74 (17) 28 (11) 184 (132) 2474 
(1229–4115)
Hoeper  et al. 
PLoS ONE 2015
[27]
mPAP 37(9) mm Hg,
mRAP 5.9 (4.8) mm Hg
CI 2.1 (0.6) l/min/m2
113 IPF
38 NSIP
68.8 (17) 28 (15.8) 251 (116) 1029
(373–2901)
the life expectancy is very poor. Functional im-
provement in the course of PAH-specific therapy 
may be occasionally seen, and it may be combi-
ned with survival benefit. Nevertheless, it has 
not been proved that the patients with severe PH 
have greater probability of achieving response to 
therapy comparing to those with non-severe PH. 
Does the result of PAH-specific therapy in PH-DPLD 
patients depend on the severity of lung disease?
This problem was addressed by experts during 
the 5th World Symposium on Pulmonary Hyperten-
sion in Nice, who concluded that patients charac-
terised by mild lung parenchymal abnormalities 
and mild disturbances of lung volumes on PFT, 
but with a haemodynamic ‘PAH phenotype’, i.e. 
severe PH with high PVR and low CO, may be 
regarded as PAH coexisting with lung disease 
(Table 2). Such patients may be treated according 
to the recommendations for PAH, keeping in mind 
the potential implications of the coexisting lung 
disease on symptoms and response to therapy [1]. 
The influence of mild to moderate lung dise-
ase on the results of PAH-specific treatment has 
been shown in studies including patients with 
PAH due to CTD, presenting with various degree 
of interstitial lung disease [49–51]. Condliffe et 
al. [49] reported worse survival of PAH-CTD pa-
tients with interstitial lung disease compared to 
those with no interstitial lung disease — 3-year 
survival rates were 28% and 47% respectively, p 
= 0.005. Le Pavec et al. [50] analysed the effect 
of PAH-specific drugs in 70 scleroderma patients 
with PAH (mean mPAP — 43 mm Hg) and inter-
stitial lung disease. The patients presented with 
restrictive ventilation pattern (mean TLC — 61% 
of predicted) and low DLCO — 34% of predicted. 
The majority of them received ERAs. No signifi-
cant changes were observed in WHO functional 
class, 6MWD or haemodynamic parameters after 
7 months of therapy [50]. The prognosis was 
poor despite treatment, only 21% of patients 
survived 3 years [50]. On the other hand, sclero-
derma patients with comparable haemodynamic 
characteristics and mode of therapy, but without 
interstitial lung disease, had much better life 
expectancy (56% survived 3 years) in the report 
of Launay et al. [51]. 
Thus, it seems that patients with PAH pheno-
type and more than mild lung disease have lower 
probability of successful PAH-specific therapy. 
Is the treatment efficacy related to the class  
of PAH-specific drugs?
One of the most important potential adverse 
effects of PAH-specific treatment is the decrease 
of oxygenation due to increased ventilation-per-
fusion mismatch. This effect may be partly depen-
dent on the type of PAH-specific drug. Ghofrani 
et al. [52] demonstrated an increase in ventilation
-perfusion mismatch and a decrease in oxygen 
saturation only in those IPF patients who received 
a single dose of intravenous epoprostenol, but not 
in those who were administered inhaled nitric 
oxide or a single oral dose of sildenafil. Milara 
et al. [53] have recently published the study on 
vascular effects of sildenafil in explanted lungs. 
They showed that sildenafil caused a vasorelaxant 
effect mainly in pulmonary arteries (PA) obtained 
from the patients with IPF without PH and from 
healthy donors. The effect was much smaller in 
PA obtained from the IPF with PH and from PAH 
lung specimens [53]. Probably, sildenafil is less 
active at sites with advanced PA remodelling 
because of markedly decreased endogenous NO, 
which is mandatory for sildenafil action.
The clinical studies performed both in DPLD 
and in PH- DPLD confirmed that sildenafil did not 
carry a significant risk of worsening of oxygena-
tion [26, 27, 39, 45]. 
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On the other hand, open label study with 
riociguat, a soluble guanylate cyclase stimulator, 
that acts independently of endogenous NO, de-
monstrated decreased oxygenation in PH due to 
various DPLD [54]. 
The data concerning ERA compound — bosen-
tan are more contradictory. Baughman et al. [46] 
reported increase of oxygen demands by > 2 l/min 
in 2 out of 23 sarcoidosis patients in the bosentan 
arm. Nevertheless, the increase of desaturation 
rate observed during 6MWT by week 16 was 
similar in the bosentan and placebo arms — 21% 
and 22% respectively [46].
Corte et al. [47] did not find a  significant 
difference in desaturation rate in IPF and NSIP 
patients treated with bosentan compared to the 
placebo arm. 
What should be the optimal outcome measure in 
a trial regarding PAH-specific treatment in PH-DPLD?
There is no consensus in terms of the best 
endpoints in clinical studies on pulmonary 
vasoactive agents in PH-DPLD. One of the early 
indicators of treatment efficacy is a decrease in NT
-proBNP serum concentration. Bonham et al. [55] 
found that NT-proBNP levels normalised in all 
patients with PH and sarcoidosis who survived 
3 years on treatment with prostacyclin and oral 
vasodilator therapy. Median NT-proBNP concen-
tration in 11 patients before treatment was 2207 
pg/ml, and 49 pg/ml in 6 of them who survived 3 
years. The decrease of serum NT-proBNP in the 
course of PAH-targeted therapy was also noted 
by Brewis et al. [26]; however, the post-treatment 
values were still markedly elevated.
Haemodynamic variables were used as pri-
mary endpoints in many open label studies 
[43, 45, 54] and some of RCTs [46, 47]. Positive 
influence of PAH-directed therapy on haemody-
namic variables was found in most open label 
studies, but this effect was not always seen in 
RCTs. Baughman et al. [46] found significant de-
crease of mPAP and PVR in sarcoidosis patients 
treated with bosentan, but Corte et al. [47] did not 
observe any influence of bosentan on haemody-
namic variables in PH due to IPF and NSIP. 
The improvement of functional status in PH
-DPLD seems to be most important as an outcome 
measure. Positive influence of PAH-specific tre-
atment on functional class (FC) was reported by 
Corte et al. and Hoeper et al. [27, 47], and increase 
in 6MWD by 20 m by Hoeper et al. [27], but it was 
not observed in the Baughman et al. [46] study. 
The data from the COMPERA registry indicated 
the possibility of survival benefit in responders to 
PAH-specific therapy, nevertheless, the survival 
benefit was not large [27].
Finally, the measures concerning the quality 
of life are gaining much attention recently. This 
issue has been addressed in STEP-IPF RCT, which 
showed significant improvement in dyspnoea in-
dex, and quality of life measured by St. George’s 
Respiratory Questionnaire (SGRQ) in IPF patients 
treated with sildenafil, compared to the placebo 
arm [39]. The sub-analysis of STEP-IPF, concer-
ning patients with known right ventricular dys-
function confirmed greater improvement in SGRQ 
and EuroQol visual analogue scores in subjects 
treated with sildenafil compared to those in the 
placebo arm [44]. Nevertheless, Corte et al. [47] 
have not found the improvement in life quality 
measured by the CAMPHOR questionnaire in the 
patients with IPF and NSIP treated with bosentan 
compared to placebo [47]. 
Summary
Based on the current status of knowled-
ge, PAH-targeted therapy is not recommended 
in PH-DPLD patients. Such treatment may be 
considered, only in experienced centres, in the 
following patients: 
1)  with severe PH and mild DPLD, as such phe-
notype might be suggestive of PAH coexisting 
with lung disease;
2)  with severe PH and severe DPLD, partici-
pating in clinical trials addressing possible 
treatment effectiveness. 
5PDEis seem to have better profile in 
PH-DPLD patients, e.g. smaller effect on venti-
lation-perfusion mismatch compared to other 
classes of PAH-specific drugs. 
Patients with severe PH and severe lung di-
sease are less likely to improve functional status, 
and consequently have less chance of survival 
improvement compared to those with severe 
PH and mild lung disease. Thus, further studies 
within PH-DPLD patients population are needed 
to answer pivotal questions on who, how and 
with what expectations could be treated with 
PAH-specific therapy.
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